Introduction
Heart failure (HF) is the most significant cardiovascular disorder encountered in clinical practice. 1 It impairs cardiac function and carries increased risks of hospital admission and mortality. 2 The occurrence and progression of HF are associated with left ventricular (LV) remodelling, which is the process of ventricular enlargement and dysfunction. Left ventricular remodelling is an adaptive process for postmyocardial infarction, hypertension, valvular heart disease, and cardiomyopathies. 3 The most common clinical pattern of cardiomyopathy is dilated cardiomyopathy (DCM). Dilated cardiomyopathy is a disease of the heart characterized by enlarged ventricles with severe systolic dysfunction. 3 Recently, gradual improvements in LV function in DCM patients have been demonstrated with appropriate treatment for HF, such as angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and b-blockers. 4 For the effective application of these medications, an early diagnosis of DCM needs to be made. Endomyocardial biopsy (EMB) is a useful method for the detection of myocardial damage. Light microscopy for diagnosis is often unsuccessful because the myocardial changes of DCM are sometimes subtle and non-specific. 5, 6 Electron microscopy allows detailed observation of myocardial cellular degeneration. 7 -9 However, the significance of ultrastructural changes in cardiomyocytes from patients with DCM have not been investigated thoroughly. Thus, the aim of the present study was to determine the implications of myocardial degeneration in DCM patients presenting initially as HF.
Methods

Patient population
This study was performed on 250 patients with idiopathic DCM. All patients underwent EMB from the LV posterolateral wall during the period January 1999 -December 2011 at the Nippon Medical School Hospital. All patients were Japanese and presented incipient decompensated HF (first-decompensated HF). Prospective patients with congenital, ischaemic, or severe valvular heart disease, histological myocarditis, or secondary metabolic, drug-induced, or inflammatory cardiomyopathies were excluded from the study. All patients enrolled in the study had systolic dysfunction [LV ejection fraction (LVEF) ,50%] without coronary artery stenosis, as assessed by coronary angiography. During the period January 1999-December 2011, EMB was performed on 410 patients, including 34 with myocarditis, 14 with hypertrophic cardiomyopathy, and seven with arrhythmogenic right ventricular cardiomyopathy. Secondary cardiomyopathy was diagnosed in 54 patients, including 21 with cardiac sarcoidosis, 6 with cardiac haemochromatosis, 6 with adriamycin-induced cardiomyopathy, and 4 with cardiac amyloidosis. After excluding patients with these illnesses, 301 patients remained.
A further 8 patients were excluded because their HF was recurring for at least the second time, 17 patients were excluded because they were lost to follow-up, and 26 patients were excluded because they declined to participate in the study. Thus, the final study population consisted of 250 patients, none of whom reported secondary cardiomyopathy or other neuromuscular disorders throughout the follow-up period. Written informed consent was obtained from all 250 patients prior to their inclusion in the study. The study itself was approved by the committee on human investigation at our institution, and was performed in accordance with the Declaration of Helsinki. Routine laboratory analyses were performed for all patients on admission. Serum B-type natriuretic peptide (BNP) levels were determined using a commercially available immunoassay kit (Shionogi Inc., Osaka, Japan). At the time of admission, transthoracic echocardiography was performed to obtain morphological and functional information. Twodimensional and M-mode and colour Doppler imaging was performed according to the standardized methods of the American Society of Echocardiography. 10 Right and left catheterizations were performed with EMB. The EMB was performed under radiographic guidance with continuous electrocardiographic monitoring. Tissue samples were collected from the LV posterolateral wall using a 7-Fr bioptome (Cordis; Johnson & Johnson Co., New Brunswick, NJ, USA) and the retrograde approach. Two EMB samples were collected and were immediately preserved in either 20% neutral-buffered formalin for light microscopy or 2.5% glutaraldehyde for electron microscopy. Left ventriculography was performed at the end of the procedure using 3 mL contrast material to confirm the absence of LV perforation. None of the patients experienced any complications in association with the EMB procedure. The type of medication prescribed for the treatment of HF on discharge was recorded.
Patients were observed from the time of cardiac catheterization (including EMB) until death, readmission because of HF, or until June 2012. Follow-up information was obtained during routine visits and by telephone contact with the patients or their physicians.
Tissue preparation and evaluation of histopathological and ultrastructural findings
Biopsy specimens for light microscopy analysis were fixed in 20% neutralbuffered formalin, embedded in paraffin, and cut into 3-mm sections. Serial sections were stained using the haematoxylin and eosin, and Elastica-Masson Goldner (EMG) methods.
Photomicrographs were taken at ×200 magnification in each case, including whole tissue sections. These photographs were taken using an NIS-Elements Documentation System (version 3.22; Nikon Instruments, Tokyo Japan) and a digital microscope camera system (DS-Ri1; Nikon). Parameters were calculated using ImageJ analysis software version 1.43 (National Institutes of Health, Bethesda, MD, USA). The following four parameters were evaluated by morphometry: (1) the size and (2) presence of perinuclear halo around cardiomyocytes, (3) the size of nuclei, and (4) the proportion of fibrosis (%F). The short diameters of nuclei and cardiomyocytes at the nuclear level were measured in 75 cells. The perinuclear halo was present in .50% of all cardiomyocytes in EMB samples.
11 %F was determined using Adobe Photoshop software version CS4 (Adobe Systems Inc., San Jose, CA, USA) to identify red (myocardium) and green (fibrotic area) in stained EMG sections, which was then used to the ratio of the fibrotic area in the myocardium as follows:
12
% F = (area of fibrosis/area of fibrosis + myocardium) × 100.
For electron microscopy, EMB samples were fixed in 2.5% glutaraldehyde and postfixed in 1% osmium tetroxide. Samples were dehydrated in a graded series of ethanol and embedded in Epok 812 (Ernest F. Fullam, Schenectady, NY, USA). Ultrathin sections were cut on an ultramicrotome with a diamond knife, stained with uranyl acetate and lead citrate, and examined under an electron microscope (JEOL-1010; JEOL, Tokyo, Japan) at 80 kV. Ultrastructurally, myofilament changes were classified as either positive (when identified in the cytoplasm of cardiomyocytes) or negative. Positive cases were divided into two groups: (i) focal derangement of myofilaments and (ii) diffuse myofilament lysis (see Figure 1) . The Ultrastructural features of cardiomyocytes in dilated cardiomyopathy 
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results of the electron microscopy of EMB samples were evaluated by two authors (T.S. and S.S.), who were blinded to the clinical background of the individuals, with each of the samples examined three times in random order. If there was a discrepancy in the evaluation of the ultrastructural findings, a final decision was reached by consensus.
Statistical analysis
Discontinuous variables were compared using the x 2 test. Continuous variables were evaluated by two-way repeated-measures analysis of variance in the case of normally distributed data and by the Kruskal -Wallis test if data were not normally distributed. To assess the relationship between histological and ultrastructural findings, multivariate logistic regression analysis was performed; the type of myofilament change and the results of morphometry were analysed. Univariate Cox regression analysis was used to identify predictors of all-cause death and the HF composite endpoint (HF death or readmission due to decompensated HF).
Variables that on univariate analysis had a P-value of ,0.1 were included in the multivariate models. Kaplan -Meier survival curves were calculated for the presence and absence of myofilament changes, and the log-rank test was used to compare the incidence rate of all-cause death and readmission. Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA) and P , 0.05 was considered significant. All data are expressed as the mean + SD.
Results
Patient characteristics
The mean follow-up time was 4.9 + 3.9 years. As of June 2012, 24 patients (10%) had died (10 cardiac-related deaths, 9 deaths due to malignancy, and 5 deaths due to infection), whereas 67 (27%) had reached the composite HF endpoint of HF death or readmission due to HF recurrence. Baseline clinical characteristics of the patients are summarized in Table 1 . None of the patients was taking diuretics or b-blockers at the time of admission. Twenty-seven patients were taking an ACEI and/or ARB. During the follow-up period, a considerable proportion of patients was started on medications for HF.
Ultrastructural changes in cardiomyocytes
Myofilament changes were apparent in degenerated cardiomyocytes ( Figure 1 ). Myofilament changes were classified as either focal derangements ( Figure 1A ) or diffuse myofilament lysis ( Figure 1B ). Focal derangement of myofilaments was identified when parts of the sarcomere were damaged, which resulted in the thick filaments of the sarcomere becoming loose ( Figure 1A ). Diffuse myofilament lysis was characterized by the disappearance of many myofilaments in cardiomyocytes. Some poorly surviving myofilaments were observed, and the region of myofilament lysis covered the entire area of the cardiomyocyte. The remaining sarcomeres were disorganized and the Z-bands in the sarcomeres had aggregated into rods. In diffuse myofilament lysis, sarcomere-depleted areas were replaced by glycogen, ribosomes, and small mitochondria ( Figure 1C) , as well as smooth endoplasmic reticulum ( Figure 1D and E) or the accumulation of large filamentous masses with diameters of 8-10 nm ( Figure 1F and G). Table 2 summarizes these findings across all patients. The results of multivariate logistic analysis to assess the relationships between histopathological and ultrastructural features are given in Table 3 .
Predictors of events
Kaplan -Meier survival curves for all-cause death and the HF composite endpoint (HF death or readmission due to recurrence of HF) in patients with and without myofilament changes are shown in Figure 2A and B. For both parameters, DCM patients with myofilament changes had a poorer prognosis than those without myofilament changes (P ¼ 0.009 and P , 0.001, respectively). There was no significant difference in all-cause death or the HF composite endpoint according to the type of myofilament alterations ( Figure 2C and D) . Candidate univariate predictors of the prognosis are given in Table 4 , whereas independent predictors are given in 
Discussion
In the present study, we demonstrated characteristic ultrastructural features in LV cardiomyocytes from DCM patients even at initial presentation with decompensated HF. The presence of myofilament changes indicated degeneration of cardiomyocytes and several morphological types were identified. Myofilament changes were more frequent in patients in the all-cause death and the HF composite (HF death or readmission due to HF recurrence) groups. These ultrastructural findings were independently related to prognosis.
Cause and significance of myofilament changes in the left ventricular myocardium
Myofilament changes may contribute to myocardial dysfunction and a poor prognosis for DCM patients. Previously, we showed that the absence of myofilament changes are one of the factors related to LVEF recovery in DCM patients. 5 DCM is a heterogeneous disease caused by myocardial abnormalities. Our observations revealed several types of myofilament changes, such as aggregation of Z-bands and smooth endoplasmic reticulum, as well as accumulation of filamentous masses similar to the desmin filaments in sarcomeres. 9 These changes may be related to degeneration of the proteins making up the sarcomere. Genetic studies have revealed that mutations in genes encoding elements of the sarcomere (e.g. cardiac b-myosin heavy chain and troponin-T 13 ) and cytoskeleton (e.g. desmin 14 and dystrophin 15 ) in DCM patients likely cause disease as a result of abnormalities in the mechanical function of cardiomyocytes. In the present study, a family history of DCM was a strong independent predictor of a poor prognosis. However, defects in causal genes account for only 35% of DCM cases, 16 with the condition being acquired in other cases as a result of viral myocarditis, autoimmunity, and/or toxic effects. 17 Ultrastructural observation of the myocardium of patients with myocarditis revealed myofilament changes in cardiomyocytes. 8, 18 Thus, myofilament changes are important findings in patients with DCM, whether the condition results from genetic mutations or through acquired disease, such as myocarditis. A combination of the ultrastructural evaluation of cardiomyocytes, molecular analysis for genes associated with sarcomeric and cytoskeletal proteins, and investigation for the presence of myocarditis may enable identification of the cause of myofilament changes, and the classification of 'DCM' as a phenotype of myocardial disease. Therapeutic strategies targeting sarcomeric and cytoskeletal degeneration will pave the way for the treatment of DCM.
Myofilament changes and histopathological elements of the left ventricular myocardium in DCM patients
The present study showed that both focal derangement of myofilaments and diffuse myofilament lysis predicted the HF composite endpoint (HF death or readmission due to recurrence of HF), whereas only diffuse myofilament lysis was an independent predictor for all-cause death. This indicates that myofilament changes may spread from a focal derangement to cover an extensive area of myofilament lysis. Diffuse myofilament lysis was related to a large cellular diameter despite the decrease in myofilaments as contractile elements of cardiomyocytes. A histopathological and ultrastructural evaluation of atrial myocytes from the goat 19 reported that glycogen accumulation seen in perinuclear sarcomere-depleted areas of cardiomyocytes may be responsible for the increase in cellular volume. However, in Replaced by large filamentous masses
Data show the number of patients with percentages in parentheses. All variables were compared using the x 2 test. the present study, the perinuclear halo identified by light microscopy was significantly correlated with focal derangement of myofilaments, not diffuse myofilament lysis. This is because myofilament changes did not always appear in the perinuclear area; it was also identified at cell margins or over the entire cardiomyocyte area. The perinuclear halo identified by light microscopy either corresponds to the storage of several cellular contents other than sarcomeres (i.e. accumulation of glycogen, mitochondria, and endoplasmic reticulum) or it is a preparation artefact of paraffin sections; in the latter case, the perinuclear halo dose not equate to myofilament changes. In evaluating myocardial specimens obtained by EMB, myocardial fibrosis was an important histopathological finding. Myocardial fibrosis of DCM is a secondary change to cellular degeneration and loss; it is a reactive accumulation of connective tissue in the interstitial space of the myocardium or replacement scarring to fill the space after myocyte loss, 6 and it appears in the advanced phase of DCM.
In the present study, focal derangement of myofilaments was responsible for a low proportion of intercellular fibrosis in the LV myocardium, whereas the diffuse type of myofilament lysis had no association with myocardial fibrosis. This is because all the subjects Tables 1 and 4 . HR, hazard ratio.
in the present study were DCM with first-decompensated HF, so the myocardial fibrosis may not yet have developed fully. Electron microscopy enables direct observation of changes in cardiomyocytes components, which is a primary pathological sign of DCM. Therefore, electron microscopy allows prediction of a prognosis for DCM patients with first-decompensated HF.
Limitations
The limitations of EMB are well known, 20 in particular the small size of the electron microscopic field. Only a limited number of cardiomyocytes (50-100 cells) can be observed, so that myocytes with myofilament changes may not appear in the field of view. However, in the present study, EMB specimens without myofilament changes were identified in 86 patients, which accounts for one-third of study subjects. Given that DCM patients with end-stage HF have extensive diffuse myocardial degeneration, 7, 21 we suggest that the actual number of damaged cardiomyocytes in the 86 patients with no myofilament changes identified in EMB specimens is very low or zero. Indeed, these patients had a good prognosis. It is very important to analyse EMB specimens from DCM patients under an electron microscope, even in those patients presenting for the first time with HF, because early evaluation enables identification of disease severity and can lead to the initiation of preventative treatment to slow the progression of DCM.
Another limitation of the present study is that many patients in both the all-cause death and the HF composite endpoint groups had higher frequency of atrial fibrillation, and lower haemoglobin levels, as revealed by multivariate analysis. Atrial fibrillation 22 and anaemia 23 are well known risk factors for HF. When discussing the association of myofilament changes and prognosis in these patients, it is difficult to exclude the effects of these complications and medications for HF. The absence of data from sex-and age-matched normal controls in the present study means that we could not compare the extent of myofilament changes in cardiomyocytes of DCM presenting as firstdecompensated HF with the situation in healthy individuals. The reason we did not have any control data is because it is very difficult to prepare EMB specimens from those control cases that are suitable for electron microscopy to enable detailed ultrastructural examination. A previous study reported that myocardial ultrastructural features, including myofilament changes, could be identified in DCM patients with end-stage HF, but were not evident in cardiac tissue samples from normal controls (autopsy cases without heart disease). 24 Because of the small number of patients who died from cardiovascular disorders during the follow-up period, we were unable to perform an analysis on the number of cardiac events.
Conclusions
Myofilament changes, either focal derangements of myofilaments or diffuse myofilament lysis, were identified even in cardiomyocytes of DCM patients with first-decompensated HF and were strongly associated with mortality and HF recurrence, regardless of the cause. Electron microscopic detection of myofilament changes in EMB specimens may be useful in determining the prognosis of DCM patients presenting initially as decompensated HF.
